Use of Lenvatinib in Neoadjuvant Setting to Achieve Total Thyroidectomy in a Case of Inoperable Follicular Thyroid Carcinoma
1Department of Endocrine Surgery, Medanta Super Speciality Hospital, Lucknow, Uttar Pradesh, India
2Department of Endocrine Surgery, Dr Ram Manohar Lohia Institute of Medical Sciences, Lucknow, India
3Department of Endocrinology, Dr Ram Manohar Lohia Institute of Medical Sciences (Dr RMLIMS), India
4-6Department of Endocrine Surgery, Dr Ram Manohar Lohia Institute of Medical Sciences (Dr RMLIMS), India
7Department of Pathology, Dr Ram Manohar Lohia Institute of Medical Sciences (Dr RMLIMS), Lucknow, India
Corresponding Author: Roma Pradhan, Department of Endocrine Surgery, Medanta Hospital, Lucknow, Uttar Pradesh, India, Phone: 9732221166, e-mail: firstname.lastname@example.org
Received on: 29 July 2022; Accepted on: 27 March 2023; Published on: 15 April 2023
Lenvatinib and other tyrosine kinase inhibitors (TKIs) are being used in locally advanced thyroid cancers like poorly differentiated and anaplastic, as well as in radiorefractory differentiated thyroid cancer (DTC). However, their role in the neoadjuvant setting for DTCs is being increasingly explored, but there are only anecdotal reports in the literature that too only for percutaneous transhepatic cholangiography (PTC). Our case seems to be the first case where it was used in follicular thyroid cancer in the neoadjuvant setting.
How to cite this article: Pradhan R, Dhanda M, Kurian NM, et al. Use of Lenvatinib in Neoadjuvant Setting to Achieve Total Thyroidectomy in a Case of Inoperable Follicular Thyroid Carcinoma. World J Endoc Surg 2022;14(2):66-67.
Source of support: Nil
Conflict of interest: Dr. Roma Pradhan is associated as the Editorial Board Member of this journal and this manuscript was subjected to this journal’s standard review procedures, with this peer review handled independently of this Editorial Board Member and her research group.
Keywords: Differentiated thyroid cancer, Endocrine surgery, Thyroid.
A 60-year-old gentleman presented with recurrent neck swelling. He was operated on (? nodulectomy) 22 years back for neck swelling, and holoprosencephaly was reported as follicular thyroid cancer. After 4 years, he developed a recurrence for which he was given radiotherapy. However, swelling continued to increase to the present size when he presented to us.
The growth continued to increase slowly, with occasional episodes of hemorrhage from the swelling and recurrent ulceration. Subsequently, the patient consulted Endocrine Surgery Outpatient Department. On examination, the patient had an ulceroproliferative mass measuring 9*5 cm fixed to the underlying muscles. The patient also had high free thyroxine and low thyroid stimulating hormone, hence started on neo-mercazole. Contrast-enhanced computed tomography (CECT) revealed a locally advanced thyroid mass—CECT showed ulceroproliferative mass in the anterior cervical space posteriorly infiltrating bilateral strap muscles and abutting thyroid gland with loss of fat planes. It was also infiltrating into b/l sternocleidomastoid muscle (R > L) with indistinct fat planes with right internal jugular vein (IJV). In view of an inoperable mass, the patient was started on lenvatinib 10 mg, which was gradually increased to up to 20 mg/day for a period of 5 months. The patient was able to tolerate it well without the need for discontinuation. He showed good response with lenvatinib with tumor reduction up to 40% and hence planned for surgery. The patient was then planned for surgery after 5 months of lenvatinib (Fig. 1). Intraoperatively tumor adhered to the strap muscles and sternocleidomastoid. IJV was reached via a posterior approach. Bilateral recurrent laryngeal nerves were identified and preserved. Primary closure was done (Fig. 2). Postoperatively, biochemical hypocalcemia was managed by oral calcium and vitamin D. Histopathology was suggestive of widely invasive follicular thyroid carcinoma. The patient is now planning for radioactive iodine treatment.
Lenvatinib and other TKI’s are being used in locally advanced thyroid cancers like poorly differentiated and anaplastic as well as in radio refractory DTC,1,2 However, their role in the neoadjuvant setting for DTCs3,4 is being increasingly explored, but there are only anecdotal reports in the literature that too only for PTC. Our case seems to be the first case where it was used in follicular thyroid cancer in the neoadjuvant setting.
1. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015;372(7):621–630. DOI: 10.1056/NEJMoa1406470
2. Cabanillas ME, Ryder M, Jimenez C. Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond. Endocr Rev 2019;40(6):1573–1604. DOI: 10.1210/er.2019-00007
3. Alshehri K, Alqurashi Y, Merdad M, et al. Neoadjuvant lenvatinib for inoperable thyroid cancer: a case report and literature review. Cancer Rep (Hoboken) 2022;5(2):e1466. DOI: 10.1002/cnr2.1466
4. Iwasaki H, Toda S, Ito H, Nemoto D, et al. A case of unresectable papillary thyroid carcinoma treated with lenvatinib as neoadjuvant chemotherapy. Case Rep Endocrinol 2020;6438352. DOI: 10.1155/2020/6438352
© The Author(s). 2022 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and non-commercial reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.